Modulation of Neuronal Death by the Transcription Factor E2F1 in Experimental Stroke

Author(s):  
J. P. MacManus ◽  
M. Jian ◽  
E. Preston ◽  
J. Webster ◽  
B. Zurakowski
2006 ◽  
Vol 27 (5) ◽  
pp. 1696-1705 ◽  
Author(s):  
Susan X. Jiang ◽  
Melissa Sheldrick ◽  
Angele Desbois ◽  
Jacqueline Slinn ◽  
Sheng T. Hou

ABSTRACT The nuclear transcription factor E2F1 plays an important role in modulating neuronal death in response to excitotoxicity and cerebral ischemia. Here, by comparing gene expression in brain cortices from E2F1+/+ and E2F1−/− mice using a custom high-density DNA microarray, we identified a group of putative E2F1 target genes that might be responsible for ischemia-induced E2F1-dependent neuronal death. Neuropilin 1 (NRP-1), a receptor for semaphorin 3A-mediated axon growth cone collapse and retraction, was confirmed to be a direct target of E2F1 based on (i) the fact that the NRP-1 promoter sequence contains an E2F1 binding site, (ii) reactivation of NRP-1 expression in E2F1−/− neurons when the E2F1 gene was replaced, (iii) activation of the NRP-1 promoter by E2F1 in a luciferase reporter assay, (iv) electrophoretic mobility gel shift analysis confirmation of the presence of an E2F binding sequence in the NRP-1 promoter, and (v) the fact that a chromatin immunoprecipitation assay showed that E2F1 binds directly to the endogenous NRP-1 promoter. Interestingly, the temporal induction in cerebral ischemia-induced E2F1 binding to the NRP-1 promoter correlated with the temporal-induction profile of NRP-1 mRNA, confirming that E2F1 positively regulates NRP-1 during cerebral ischemia. Functional analysis also showed that NRP-1 receptor expression was extremely low in E2F1−/− neurons, which led to the diminished response to semaphorin 3A-induced axonal shortening and neuronal death. An NRP-1 selective peptide inhibitor provided neuroprotection against oxygen-glucose deprivation. Taken together, these findings support a model in which E2F1 targets NRP-1 to modulate axonal damage and neuronal death in response to cerebral ischemia.


2001 ◽  
Vol 75 (1) ◽  
pp. 91-100 ◽  
Author(s):  
Sheng T. Hou ◽  
Debbie Callaghan ◽  
Marie-Christine Fournier ◽  
Irene Hill ◽  
Liping Kang ◽  
...  

2007 ◽  
Vol 25 (1) ◽  
pp. 17-26 ◽  
Author(s):  
Saori Shimizu ◽  
Muhammad Z. Khan ◽  
Randi L Hippensteel ◽  
Anjum Parkar, ◽  
Ramesh Raghupathi ◽  
...  

2010 ◽  
Vol 31 (2) ◽  
pp. 757-766 ◽  
Author(s):  
Gina Ziegler ◽  
Dorette Freyer ◽  
Denise Harhausen ◽  
Uldus Khojasteh ◽  
Wilfried Nietfeld ◽  
...  

Reduced infarct volume in TLR2-knockout mice compared with C57Bl/6 wild-type mice has recently been shown in experimental stroke and confirmed in this study. We now also show a significant decrease of CD11b-positive cell counts and decreased neuronal death in the ischemic hemispheres of TLR2-deficient mice compared with C57Bl/6wt mice 2 days after transient focal cerebral ischemia. To examine the potential benefit of intravascular TLR2 inhibition, C57Bl/6wt mice were treated intraarterially with TLR2-blocking anti-TLR2 antibody (clone T2.5) after 45 minutes of cerebral ischemia and compared with control antibody (isotype) treated wild-type mice. Whereas T2.5-treated mice had no reduction in infarct volumes at 48 hours after reperfusion, they did have decreased numbers of CD11b-positive inflammatory cells and decreased neuronal death compared with isotype-treated control mice. Comparison of the isotype antibody treatment to control (saline) treatment showed no effects on infarct volumes or neuronal survival. However, mice treated with the control isotype antibody had increased numbers of CD11b-positive inflammatory cells compared with saline-treated animals. Thus, antibody treatment itself (i.e., control isotype antibody, but potentially of any antibody) may have adverse effects and limit therapeutic benefit of anti-TLR2-antibody therapy. We conclude that TLR2 mediates leukocyte and microglial infiltration and neuronal death, which can be attenuated by TLR2 inhibition. The TLR2 inhibition in vivo improves neuronal survival and may represent a future stroke therapy.


Neuroreport ◽  
1999 ◽  
Vol 10 (13) ◽  
pp. 2711-2714 ◽  
Author(s):  
J P. MacManus ◽  
C J. Koch ◽  
M Jian ◽  
T Walker ◽  
B Zurakowski

2012 ◽  
Vol 288 (1) ◽  
pp. 368-381 ◽  
Author(s):  
Raghu Gogada ◽  
Neelu Yadav ◽  
Junwei Liu ◽  
Shaohua Tang ◽  
Dianmu Zhang ◽  
...  

2021 ◽  
Author(s):  
Weiliang He ◽  
Xiaochao Tian ◽  
Kaihua Zhang ◽  
Hebo Wang

Abstract BackgroundBrain plasticity including axonal sprouting has been recognized in restoring motor function in ischemic stroke. Mitochondrion plays a crucial role in determining axonal sprouting in ischemic injury. Taurine (TAU) could protect brain against experimental stroke as one of the richest amino acids. However, the role of TAU on axonal sprouting and the specific potential mechanism on mitochondria of stroke were unclear. MethodsFocal cerebral cortical ischemia in C57BL/6 mice was preceded. Motor function was assayed by the Rota-Rod test on D7, D14, and D28 after stroke. Axonal sprouting was detected using immunocytochemistry with biotinylated dextran amine (BDA). The expressions of mitochondrial DNA (mtDNA), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PCG-1a) and Transcription factor A of mitochondria (TFAM) were measured by RT-qPCR. ResultsTAU treatment significantly recovered the motor function of focal cerebral cortical ischemic mice. And TAU promoted axonal sprouting. It was also observed that TAU enhanced mtDNA content, increased the levels of Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PCG-1a) and Transcription factor A of mitochondria (TFAM). ConclusionsCollectively, the data illustrated that TAU exerted a promoting influence on axonal sprouting, through mitochondrial improvement in cerebral ischemic stroke.


Sign in / Sign up

Export Citation Format

Share Document